30 publications
Name | Date | Type | Actions |
---|---|---|---|
Universal registration document 2023 XBRL version Universal Registration Document including the Annual Financial Report |
24/04/2024 | Reference document | |
Universal registration document 2023 Universal Registration Document including the Annual Financial Report |
24/04/2024 | Reference document | |
Sustainable development, an integral part of Vetoquinol Vetoquinol's corporate vision underlines its ambition for its entire ecosystem. This vision creates a dynamic for sustainable development by stating that by 2033 the company will be "the most agile animal health laboratory where employees, experts, partners, and customers work together to create customized solutions dedicated to animal health for a better planet". |
13/09/2023 | Press releases communication | |
Mastaplex and Vetoquinol announce distribution agreement Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest.. |
27/07/2023 | Press releases communication | |
Growth driven by innovation Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy. |
13/06/2023 | Press releases communication | |
3rd generation appointed chairman of the board of directors of VETOQUINOL SA At the Combined General Meeting it was also announced that Mr. Etienne Frechin will resign as Chairman of the Board of Vetoquinol, effective 1st July 2023. Mr. Etienne Frechin will remain a Director of the company, hence continuing to share his broad experience. On 25 May 2023, the Board of Directors appointed Mr. Matthieu Frechin, Chief Executive Officer of the Group, as Chairman of the Board of Directors of Vetoquinol effective 1st July 2023. |
25/05/2023 | Press releases communication | |
Universal registration document 2022 Universal Registration Document including the Annual Financial Report |
05/05/2023 | Reference document | |
Essential products Essential products for the most common needs |
27/04/2023 | Press releases communication | |
Worlds Top 10 The animal health company is firmly established in the world's Top 10. |
27/04/2023 | Press releases communication | |
Document d’enregistrement universel (URD) 2022 version XBRL Document d'enregistrement universel 2022 incluant le rapport financier annuel |
13/04/2023 | Reference document | |
A visionary strategy The key steps of a visionary strategy |
03/04/2023 | Press releases communication | |
Serving animal Health - 90 years Serving animal Health for over 90 years |
06/03/2023 | Press releases communication | |
In 2023 Vetoquinol celebrates its 90th anniversary. - 90 years The story of an incredible family saga. From a regional pharmaceutical laboratory to a world leader in animal health. |
31/01/2023 | Press releases communication | |
CALENDAR 2023 Stock exchange market – non authorized periods The "negative windows" are the abstention periods during which it is forbidden to trade in the Company's securities. |
13/01/2023 | Financial Documents | |
Universal registration document 2021 Universal Registration Document including the Annual Financial Report |
05/05/2022 | Reference document | |
2020 Universal registration document 2020 universal registration document including the Annual Financial Report |
28/04/2021 | Reference document | |
Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health. |
08/02/2021 | press release excluding results | |
2019 Universal registration document Note to recipient of this document: this is the translation of an extract of the Universal Registration Document and Annual Financial Report for the year ended December 31, 2019. The original French document was filed with the AMF (French Financial Markets Authority) on April 23, 2020.
|
23/04/2020 | Reference document | |
2018 registration document Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2018.
|
29/04/2019 | Reference document | |
2017 Registration document 2017 Registration document |
23/04/2018 | Reference document | |
2016 Registration document Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2016. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2017. |
26/04/2017 | Reference document | |
2015 Registration document Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2015. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2016. |
27/04/2016 | Reference document | |
Registration Document 2014 Registration Document 2014 |
20/04/2015 | Reference document | |
Reference Document 2013 Reference Document 2013 |
14/04/2014 | Reference document | |
Reference Document 2012 (in french) Reference Document 2012 (in french) |
16/04/2013 | Reference document | |
Reference document 2011 Reference document 2011 |
26/04/2012 | Reference document | |
Reference document 2010 Reference document 2010 |
27/04/2011 | Reference document | |
Reference Document 2009 Reference Document 2009 |
23/04/2010 | Reference document | |
2008 financial report Laboratoire pharmaceutique vétérinaire familial et indépendant, Vétoquinol se consacre exclusivement à la santé animale. Son activité est volontairement équilibrée entre animaux de rente et animaux de compagnie. |
04/05/2009 | Reference document | |
Financial report 2007 Consolidated 2007 figures are even better than the targets in the business plan we presented for the initial public offering (IPO) in November 2006. |
15/05/2008 | Reference document |